secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001628280-23-041317
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics announces positive Phase 1 data for CFT7455 in relapsed/refractory multiple myeloma
--------------------------------------------------------------------------------

- Monotherapy dose escalation complete; 22 patients, median 7 prior therapies; 1 PR at 75 µg daily in BCMA-refractory patient.
- Combination with dexamethasone: 9 patients; 1 sCR and 1 PR at 37.5 µg daily, both BCMA refractory.
- CFT7455 well tolerated; no DLTs leading to discontinuation; common Grade 3+ AE: neutropenia (n=11).
- Optimal dosing schedule 14 days on/14 days off; immunomodulatory CD8+ T-cell activation observed.
- Dose escalation continues for combination and NHL; full Phase 1 data expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023041317/0001628280-23-041317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023041317/cccc-20231212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-041317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer